Mineralys Therapeutics (MLYS) Accumulated Expenses (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Accumulated Expenses data on file, last reported at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 4.53% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $13.6 million (up 4.53% YoY), and the FY2025 full-year result was $13.1 million, down 7.56% from the prior year.
• Accumulated Expenses advanced to $13.6 million in Q1 2026, from $13.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $28.2 million in Q3 2024 to a low of $4.0 million in Q2 2023.
• A 5-year average of $14.4 million and a median of $13.3 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 565.42% in 2024 and retreated 28.78% in 2025, its largest moves.
• Tracing MLYS's Accumulated Expenses over 5 years: stood at $6.2 million in 2022, then soared by 60.41% to $9.9 million in 2023, then surged by 43.38% to $14.2 million in 2024, then fell by 7.56% to $13.1 million in 2025, then climbed by 3.86% to $13.6 million in 2026.
• Business Quant data shows MLYS's Accumulated Expenses at $13.6 million in Q1 2026, $13.1 million in Q4 2025, and $22.4 million in Q3 2025.